Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma
- 1 June 2007
- journal article
- Published by Elsevier in Leukemia Research
- Vol. 31 (6) , 779-782
- https://doi.org/10.1016/j.leukres.2006.08.002
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myelomaBlood, 2005
- Clinical Outcomes in t(4;14) Multiple Myeloma: A Chemotherapy-Sensitive Disease Characterized by Rapid Relapse and Alkylating Agent ResistanceJournal of Clinical Oncology, 2005
- A phase 2 study of two doses of bortezomib in relapsed or refractory myelomaBritish Journal of Haematology, 2004
- The proteasome: a suitable antineoplastic targetNature Reviews Cancer, 2004
- Detection of Chromosome 13q Deletions and IgH Translocations in Patients with Multiple Myeloma by FISH: Comparison with Karyotype AnalysisLeukemia & Lymphoma, 2004
- Single versus Double Autologous Stem-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2003
- A Phase 2 Study of Bortezomib in Relapsed, Refractory MyelomaNew England Journal of Medicine, 2003
- Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapyBlood, 2002
- Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapyBlood, 2001
- A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple MyelomaNew England Journal of Medicine, 1996